Lax-Asab powder	placebo	Improvement in other measured outcomes concerning defecation difficulty	11072	11218	All the other measured outcomes concerning defecation difficulty were significantly improved in patients receiving Lax-Asab compared with placebo.
Lax-Asab powder	placebo	mean of weekly defecation frequency increase	1192	1401	The mean of weekly defecation frequency increased in both groups; from 1.8 ± 0.41 to 4.8 ± 1.12 times in patients who received Lax-Asab and from 1.7 ± 0.44 to 2.2 ± 0.61 times in patients who received placebo.
Lax-Asab powder	placebo	tolerability of treating patients with chronic functional constipation	11363	11532	Side effects were reported by three patients who received placebo and by seven who received Lax-Asab [odds ratio = 3.05; 95% confidence interval (0.65–14.13); p = 0.27].
Lax-Asab powder	placebo	side effects observed	1631	1745	There was no statistically significant difference between the two groups with regard to the side effects observed.
Lax-Asab powder	placebo	efficacy of treating patients with chronic functional constipation	10740	11256	The mean of weekly defecation times increased in both groups (p = 0.001); from 1.8 ± 0.41 to 4.8 ± 1.12 times in patients receiving Lax-Asab and from 1.7 ± 0.44 to 2.2 ± 0.61 times in patients receiving placebo. A time–treatment interaction showed that this increase was significantly higher in the intervention group (p < 0.0001). All the other measured outcomes concerning defecation difficulty were significantly improved in patients receiving Lax-Asab compared with placebo. The results are presented in Table 1.
Lax-Asab powder	placebo	efficacy of treating patients with chronic functional constipation	1746	1898	This study confirms the efficacy and tolerability of an Iranian herbal preparation, Lax-Asab, in treating patients with chronic functional constipation.
Lax-Asab powder	placebo	mean of weekly defecation frequency increase	1192	1508	The mean of weekly defecation frequency increased in both groups; from 1.8 ± 0.41 to 4.8 ± 1.12 times in patients who received Lax-Asab and from 1.7 ± 0.44 to 2.2 ± 0.61 times in patients who received placebo. A time–treatment interaction showed that this increase was significantly higher in the intervention group.
